ArticleClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2026
Feasibility, safety, and clinical outcomes analysis of dense-lattice radiation therapy in palliative care for cancer patients´.
Article in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimThe management of patients with advanced cancer, especially in the presence of bulky tumors, presents significant challenges for oncology practice, despite advances in conventional RT. Considering the dosimetry advantages of our dense-LRT protocol, we aimed for the first time to assess the safety and feasibility of the use of dense-LRT as exclusive radiation treatment for palliative care in locally advanced/metastatic cancer patients.
methodsPatients diagnosed with locally advanced and/or metastatic tumors and/or inoperable patients with a high burden of disease with cancers of different etiologies were included in this prospective study of dense-Lattice Radiotherapy from October-2022, until February-2025. The dense-LRT treatment characteristics have been already published. Our study aimed to analyze the use of dense-LRT as exclusive radiation treatment, which was designed as preplanned 3 patients' cohorts in a 1:1:1 protocol. Cohort 1: 24 Gy-LRT + EBRT. Cohort 2: exclusive 24 Gy-LRT. Cohort 3: exclusive 36 Gy-LRT. The primary endpoints of the study were the feasibility and safety of the proposed treatment protocol.
resultsThe dense-LRT protocol was feasible and safe with no grade 3 acute or late toxicity reported. The 3 month CR and PR response rates were 2/20 (10%) and 14/20(70%), resulting in an objective response rate of 80%. The 1-year actuarial survival was 52.1%. The Hybrid and the accelerated cohorts showed better clinical response rates. The hybrid protocol showed a slightly increase in mild adverse effects.
conclusionOur preliminary results could suggest that a high-dose accelerated LRT protocol (36 Gy/3fractions/5 days) is effective and a safe in the palliative treatment of bulky tumors. Further study is needed to define its role in palliative cancer care.
Indexed as
Identifiers
41708965What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.